Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”)
today announced that Mr. Peter Greenleaf, Chief Executive Officer, will
present a corporate overview at the RBC Capital Markets Global
Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am
ET) in New York, NY.

The presentation will be webcast live and can be accessed via the
investor section of the Aurinia website, www.auriniapharma.com.
A replay of the presentation will also be archived on the Company
website following the event.

About Aurinia

Aurinia Pharmaceuticals Inc. is a late clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations impacted by serious
diseases with a high unmet medical need. The company is currently
developing voclosporin, an investigational drug, for the potential
treatment of lupus nephritis (LN), focal segmental glomerulosclerosis
(FSGS), and dry eye syndrome (DES). The company is headquartered in
Victoria, British Columbia and focuses its development efforts globally.
For further information, see our website at
www.auriniapharma.com.

Contacts

Investor Contact:
Glenn Schulman, PharmD, MPH
Corporate
Communications
gschulman@auriniapharma.com
or
Media
Contact:

Christopher Hippolyte
212-364-0458
Christopher.Hippolyte@inventivhealth.com